{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095419","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.551063+00:00","generated_at":"2026-05-31T10:06:17.234193+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway","bullets":["Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.","R&D expenses $28.9M in Q2 2024 vs $18.8M Q2 2023, up $10.2M on pipeline advancement.","G&A expenses $7.1M in Q2 2024 vs $6.2M Q2 2023, up $0.9M on higher personnel costs.","ORIC-114 Phase 1b dose escalation complete; expansion cohorts in EGFR/HER2 mutant NSCLC dosed; data expected H1 2025.","ORIC-944 combo dosing initiated with NUBEQA and ERLEADA; clinical trial agreements with Bayer and J&J."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095419","json":"https://secwatch.observer/filing/0000950170-24-095419.json","markdown":"https://secwatch.observer/filing/0000950170-24-095419.md","text":"https://secwatch.observer/filing/0000950170-24-095419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/0000950170-24-095419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/oric-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:06:17.234193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}